What does Purna Pharmaceuticals do?

Purna Pharmaceuticals is registered with the CBE as active in: Vervaardiging van geneesmiddelen. Public Limited, started on 4 April 1986, 1 establishment.

What is the address of Purna Pharmaceuticals?

The registered office of Purna Pharmaceuticals is located at Rijksweg 17, 2870 Puurs-Sint-Amands.

Is Purna Pharmaceuticals still active?

Yes. According to the CBE (29 October 2026) Purna Pharmaceuticals is active, legal situation “Normale toestand”, started on 4 April 1986.

Is Purna Pharmaceuticals registered on Peppol?

Yes, Purna Pharmaceuticals is registered on the Peppol network with ID 0208:0428742176.

What is the enterprise number of Purna Pharmaceuticals?

The enterprise number of Purna Pharmaceuticals is BE0428742176.

When was Purna Pharmaceuticals founded?

Purna Pharmaceuticals was founded on 4 April 1986.

Who are the directors of Purna Pharmaceuticals?

According to the 2025 annual accounts, the directors of Purna Pharmaceuticals are: BART M.J. PEETERS BV, David J. Parker, Hidde Van Kerckhoven, LEA SMETS, CREAFUND ASSET MANAGEMENT NV, RAYMOND VAN GUCHT.

Is Purna Pharmaceuticals a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 4 April 1986; 5 annual accounts filed, latest fiscal year 2025; 6 directors known from the annual account.

How much profit did Purna Pharmaceuticals make in 2025?

Purna Pharmaceuticals posted a profit after taxes of € 2,819,137 in financial year 2025.

What is the revenue of Purna Pharmaceuticals?

In its most recent annual accounts (2025), Purna Pharmaceuticals reported revenue of € 43,231,454.

How much does an employee at Purna Pharmaceuticals earn?

The average wage cost per full-time employee at Purna Pharmaceuticals was € 69,000 in 2025: staff costs of € 12.6 million for 182.6 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Purna Pharmaceuticals have?

According to the 2025 annual accounts, Purna Pharmaceuticals has 182.6 full-time equivalents (FTE).

Does Purna Pharmaceuticals have a website?

Yes, Purna Pharmaceuticals has a website at purna.be.

Purna Pharmaceuticals (Public Limited)

Dossier Purna Pharmaceuticals, printed on 29 October 2026 from databakkes.be/en/0428742176/purna-pharmaceuticals. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Purna Pharmaceuticals from Puurs-Sint-Amands, company number BE0428742176, closed financial year 2025 with a result of € 2.8 million after tax. For that financial year Purna Pharmaceuticals recorded revenue of € 43.2 million and equity of € 19.4 million. Compared with financial year 2024, the result moved from € 2.7 million to € 2.8 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 5, 2026.

What it is worth Growing

€ 19.4 million

▲ 16% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 2.8 million

▲ 4% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 173,324

▲ 250% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 6.8 million.

People and assets in 2025

Full-time equivalents

182.6

▲ 1.4 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost Staff costs are payroll only. Director pay sits with services and miscellaneous goods: € 9 million in 2025, together with rent, insurance, accountants and other services. The accounts do not split that further.

€ 12.6 million

▲ 7% vs 2024

€ 69,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 2.4 million

▼ 30% vs 2024

Of which on lease € 2.3 million.

Debts at end 2025

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 7.8 million

▼ 28% vs 2024

€ 2.1 million is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Owed to suppliers

€ 4 million

▼ 30% vs 2024

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 59 days on average.

Taxes and wages

€ 1.3 million

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 37,426,127 Revenue 2022: € 37,426,127 First fiscal year in the series	€ 37,744,283 Revenue 2023: € 37,744,283 ▲ 1% vs 2022 (€ 37,426,127) Favourable step	€ 45,949,321 Revenue 2024: € 45,949,321 ▲ 22% vs 2023 (€ 37,744,283) Favourable step	€ 43,231,454 Revenue 2025: € 43,231,454 ▼ 6% vs 2024 (€ 45,949,321) Unfavourable step	▼ 6%
Profit after taxes	€ -744,999 Profit after taxes 2022: € -744,999 First fiscal year in the series	€ -3,378,000 Profit after taxes 2023: € -3,378,000 ▼ € 2.6 million vs 2022 (€ -744,999) Unfavourable step	€ 2,705,540 Profit after taxes 2024: € 2,705,540 ▲ € 6.1 million vs 2023 (€ -3,378,000) Favourable step	€ 2,819,137 Profit after taxes 2025: € 2,819,137 ▲ 4% vs 2024 (€ 2,705,540) Favourable step	▲ 4%
Equity	€ 8,178,236 Equity 2022: € 8,178,236 First fiscal year in the series	€ 11,147,359 Equity 2023: € 11,147,359 ▲ 36% vs 2022 (€ 8,178,236) Favourable step	€ 16,695,743 Equity 2024: € 16,695,743 ▲ 50% vs 2023 (€ 11,147,359) Favourable step	€ 19,386,429 Equity 2025: € 19,386,429 ▲ 16% vs 2024 (€ 16,695,743) Favourable step	▲ 16%
Total debts	€ 18,612,736 Total debts 2022: € 18,612,736 First fiscal year in the series	€ 19,776,329 Total debts 2023: € 19,776,329 ▲ 6% vs 2022 (€ 18,612,736) Unfavourable step	€ 19,424,990 Total debts 2024: € 19,424,990 ▼ 2% vs 2023 (€ 19,776,329) Favourable step	€ 14,895,091 Total debts 2025: € 14,895,091 ▼ 23% vs 2024 (€ 19,424,990) Favourable step	▼ 23%
Cash	€ 61,981 Cash 2022: € 61,981 First fiscal year in the series	€ 63,600 Cash 2023: € 63,600 ▲ 3% vs 2022 (€ 61,981) Favourable step	€ 49,511 Cash 2024: € 49,511 ▼ 22% vs 2023 (€ 63,600) Unfavourable step	€ 173,324 Cash 2025: € 173,324 ▲ 250% vs 2024 (€ 49,511) Favourable step	▲ 250%
Land & buildings	€ 5,921,751 Land & buildings 2022: € 5,921,751 First fiscal year in the series	€ 11,992,187 Land & buildings 2023: € 11,992,187 ▲ 103% vs 2022 (€ 5,921,751) Unchanged	€ 14,403,316 Land & buildings 2024: € 14,403,316 ▲ 20% vs 2023 (€ 11,992,187) Unchanged	€ 13,927,441 Land & buildings 2025: € 13,927,441 ▼ 3% vs 2024 (€ 14,403,316) Unchanged	▼ 3%
Retained profit	€ 4,624,439 Retained profit 2022: € 4,624,439 First fiscal year in the series	€ 1,246,439 Retained profit 2023: € 1,246,439 ▼ 73% vs 2022 (€ 4,624,439) Unfavourable step	€ 3,951,979 Retained profit 2024: € 3,951,979 ▲ 217% vs 2023 (€ 1,246,439) Favourable step	€ 6,771,116 Retained profit 2025: € 6,771,116 ▲ 71% vs 2024 (€ 3,951,979) Favourable step	▲ 71%
Bank debt	€ 11,664,806 Bank debt 2022: € 11,664,806 First fiscal year in the series	€ 12,121,027 Bank debt 2023: € 12,121,027 ▲ 4% vs 2022 (€ 11,664,806) Unfavourable step	€ 10,839,285 Bank debt 2024: € 10,839,285 ▼ 11% vs 2023 (€ 12,121,027) Favourable step	€ 7,821,637 Bank debt 2025: € 7,821,637 ▼ 28% vs 2024 (€ 10,839,285) Favourable step	▼ 28%
Balance sheet total	€ 26,819,969 Balance sheet total 2022: € 26,819,969 First fiscal year in the series	€ 30,952,685 Balance sheet total 2023: € 30,952,685 ▲ 15% vs 2022 (€ 26,819,969) Unchanged	€ 36,149,730 Balance sheet total 2024: € 36,149,730 ▲ 17% vs 2023 (€ 30,952,685) Unchanged	€ 34,310,517 Balance sheet total 2025: € 34,310,517 ▼ 5% vs 2024 (€ 36,149,730) Unchanged	▼ 5%
Employees (FTE)	190.7 Employees (FTE) 2022: 190.7 First fiscal year in the series	188.7 Employees (FTE) 2023: 188.7 ▼ 2 vs 2022 (190.7) Unchanged	181.2 Employees (FTE) 2024: 181.2 ▼ 7.5 vs 2023 (188.7) Unchanged	182.6 Employees (FTE) 2025: 182.6 ▲ 1.4 vs 2024 (181.2) Unchanged	▲ 1.4

Key figures of Purna Pharmaceuticals, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Purna Pharmaceuticals?

What happened at Purna Pharmaceuticals in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2032 David J. Parker stepped down as director. NBB
2032 Hidde Van Kerckhoven stepped down as director. NBB
Jun 5, 2026 New annual accounts for financial year 2025: profit of € 2.8 million (▲ 4% vs 2024). Source: NBB ↗
2026 David J. Parker became a director. NBB
2026 BART M.J. PEETERS BV stepped down as director. NBB
2026 Hidde Van Kerckhoven became a director. NBB
2026 LEA SMETS stepped down as director. NBB
2026 CREAFUND ASSET MANAGEMENT NV stepped down as director. NBB

In short

From € 744,999 loss in 2022 to € 2.8 million profit in 2025.

Paid € 122,866 in corporate taxes since 2022.

Best year ever: 2025, with € 2.8 million profit.

Pays suppliers within 59 days on average.

Original PDFs at the National Bank ↗

Management

Directors

According to the 2025 annual accounts

BART M.J. PEETERS BV

Managing director · represented by BART PEETERS

since 2021 · until 2026

David J. Parker

Director

since 2026 · until 2032

Hidde Van Kerckhoven

Director

since 2026 · until 2032

LEA SMETS

Director

since 2021 · until 2026

CREAFUND ASSET MANAGEMENT NV

Director · represented by RUTH DE WULF

Also active at: Beddeleem, DIRESCO, CREALOAN, Cu.be Solutions, JOVEGI, MOBILE LOCKER, Quartz Holding, CARE INVESTCO +2 more

since 2021 · until 2026

RAYMOND VAN GUCHT

Chairman of the board

since 2021 · until 2026

Establishments

Establishment units

Physical locations of this company

Registered office

Rijksweg 17

2870 Puurs-Sint-Amands

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

Inno Pharma

€ -66 gross margin · 2025

Montana BidCo

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS purna.be

Canonical: https://www.purna.be/

Technologies

All in One SEODiviElementorFacebook PixelGoogle AnalyticsGoogle Tag ManagerNginxPHPW3 Total CacheWPMLWordPressiubendajQuerylazysizes

Hosting & Email

Email provider

Barracuda

Hosting

COMBELL-AS, BE

Website info

HTTPS Ja

Languages EN, NL

Features

Ads

Security

✓ HTTPS

✓ SPF

✓ DMARC

Network

✓ IPv6

Details

Company number

0428.742.176

VAT number

BE 0428.742.176

Registered office

Rijksweg 17, 2870 Puurs-Sint-Amands

Names & denominations

Purna Pharmaceuticals

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

4 April 1986

Peppol

Active · Active since 1 Jan 2001

Contact

purna.be

Activities · NACE

Vervaardiging van geneesmiddelen

Vervaardiging van overige farmaceutische producten

Vervaardiging van overige farmaceutische preparaten

Groothandel in farmaceutische en medische artikelen

Groothandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗

Purna Pharmaceuticals

Financials

What happened to Purna Pharmaceuticals?

Management

Directors

Establishments

Establishment units

Who else lives here?

Website

Technologies

Hosting & Email

Website info

Features

Security

Network

Details

Frequently asked questions